Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

International Journal of Clinical Oncology

Volumn 17, Issue 4, 2012, Pages 395-398

  Takimoto, Takayuki ^a   Nakabori, Tasuku ^a   Osa, Akio ^a   Morita, Satomu ^a   Terada, Haruko ^a   Oseto, Susumu ^a   Iwazawa, Takashi ^a   Abe, Kinya ^a  

^a TOYONAKA MUNICIPAL HOSPITAL   (Japan)

Author keywords

2 Microglobulin; Chronic renal failure; Docetaxel; Non small cell lung cancer (NSCLC); Tubular nephrotoxicity

Indexed keywords

BETA 2 MICROGLOBULIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; N ACETYL BETA GLUCOSAMINIDASE; PEMETREXED;

ADULT; AGED; ARTICLE; BETA 2 MICROGLOBULIN BLOOD LEVEL; BETA 2 MICROGLOBULIN URINE LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; N ACETYL BETA GLUCOSAMINIDASE URINE LEVEL; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RADIATION PNEUMONIA; SIDE EFFECT; STOMACH CANCER; UREA NITROGEN BLOOD LEVEL; URINE DENSITY; UROGENITAL SYSTEM PARAMETERS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KIDNEY TUBULES; MALE; MIDDLE AGED; NEOPLASM STAGING; RENAL INSUFFICIENCY; TAXOIDS;

EID: 84867334784     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0304-5     Document Type: Article

References (18)

1. Launay-Vacher V, Etessami R, Janus N et al (2009) Lung cancer and renal insufficiency: Prevalence and anticancer drug issues. Lung 187:69-74
2. Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev 21:33-64
3. Sahni V, Choudhury D, Ahmed Z (2009) Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 5:450-462
4. Kudoh S, Takeda K, Nakagawa K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657-3663
5. Douillard JY, Laporte S, Fossella F et al (2007) Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the firstline treatment of advanced non-small-cell lung cancer: Metaanalysis of seven randomized clinical trials. J Thorac Oncol 2:939-946
6. Extra JM, Rousseau F, Bruno R et al (1993) Phase I and pharmacokinetics study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042
7. Shou M, Martinet M, Korzekwa KR et al (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401
8. Mencoboni M, Olivieri R, Vannozzi MO et al (2006) Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodialyzed patient. Chemotherapy 52:147-150
9. Jones BR, Bhalla RB, Mladek J et al (1980) Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 27:557-562
10. Daugaard G, Abildgaard (1989) Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 25:1-9
11. Kawai Y, Taniuchi S, Okahara S (2005) Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 28:1385-1388
12. Dentino M, Luft FC, Yum M et al (1978) Long term effect of cisdiamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41:1274-1281
13. Hochegger K, Lhotta K, Mayer G et al (2007) Pharmacokinetics analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant 22(1):289-290
14. Riccardi F, Lorenzo GD, Buonerba C et al (2010) Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer. World J Surg Oncol 8:8
15. Goren MP, Pratt CB, Viar MJ et al (1989) Tubular nephrotoxicity during long-term ifosfamide and mesna therapy. Cancer Chemother Pharmacol 25:70-72
16. Goren MP, Forastiere AA, Wright RK et al (1987) Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol 19:57-60
17. Kuhn JA, Argy WP, Rakowski TA et al (1980) Nephrotoxicity of cis-diamminedichloroplatinum (II) as measured by urinary bglucuronidase. Cancer Treat Rep 64:1083-1086
18. Reece PA, Stafford I, Russell J et al (1986) Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 4:1392-1398